Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

728
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
728
Prodrugs01:30

Prodrugs

4.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.6K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

609
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
609
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026
Same author

Population differences in reproductive resource allocation and heterosis in the invasive vector Aedes albopictus.

Parasites & vectors·2026
Same author

Uncovering Insights Into the Biology of Mycobacterium tuberculosis Using Genetic Tools.

MicrobiologyOpen·2025
Same author

Advancing the antituberculosis activity of nitropicolinic acids and amides.

European journal of medicinal chemistry·2025
Same author

Targeting virulence in Mycobacterium tuberculosis and nontuberculous mycobacteria: Focus on anti-infective drug design.

Drug discovery today·2025

Related Experiment Video

Updated: Mar 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

New prodrugs against tuberculosis.

Giorgia Mori1, Laurent Roberto Chiarelli1, Giovanna Riccardi1

  • 1Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, via Ferrata 1, 27100 Pavia, Italy.

Drug Discovery Today
|September 22, 2016
PubMed
Summary

Prodrugs enhance drug delivery and efficacy, offering new strategies for tuberculosis treatment. This approach, once a last resort, is now vital in early drug development for more effective antitubercular agents.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Related Experiment Videos

Last Updated: Mar 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Development

Background:

  • The prodrug concept, introduced in 1958, aims to optimize drug properties.
  • Prodrugs improve solubility, bioavailability, permeability, absorption, distribution, metabolism, excretion, and reduce toxicity.
  • Initially a last resort, prodrug strategies are now integrated early in drug development.

Purpose of the Study:

  • To highlight the significance of the prodrug approach in modern drug discovery.
  • To emphasize the role of prodrugs in developing novel therapeutics for tuberculosis (TB).

Main Methods:

  • Review of the historical and current applications of prodrugs in pharmaceutical research.
  • Analysis of existing antitubercular agents as examples of prodrugs.

Main Results:

  • Prodrugs offer versatile solutions for overcoming pharmacokinetic and toxicological challenges.
  • Key antitubercular drugs like isoniazid and ethionamide function as prodrugs.
  • The prodrug strategy is crucial for the rational design of improved TB treatments.

Conclusions:

  • The prodrug approach is a fundamental strategy in contemporary drug development.
  • Leveraging prodrugs is essential for creating next-generation antitubercular therapies.
  • This approach holds significant potential for advancing tuberculosis treatment paradigms.